• Actinium Pharmaceuticals released a Phase 1 abstract evaluating long-term safety of Actimab-A with CLAG-M chemotherapy in relapsed or refractory acute myeloid leukemia.
• Results will be presented at the American Society of Hematology annual meeting on December 13, 2026.
• Safety findings support further evaluation of Actimab-A as a potential treatment backbone across mutations, with follow-up assessing blood-count recovery and delayed organ toxicity.
• Efficacy results presented at ASH 2022 showed clinical activity in patients previously treated with venetoclax or whose leukemia carried TP53 mutations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040905PR_NEWS_USPR_____NY88514) on November 04, 2026, and is solely responsible for the information contained therein.